E-viri
Recenzirano
-
Kahán, Zsuzsanna; Spanik, Stanislav; Wagnerova, Maria; Skacel, Tomas; Planko, Barbara; Fitzthum, Elisabeth; Lindner, Elisabeth; Soldatenkova, Victoria; Zielinski, Christoph C.; Brodowicz, Thomas
Breast cancer research and treatment, 12/2008, Letnik: 112, Številka: 3Journal Article
Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC 60 providing little benefit over standard chemotherapy and FEC 100 associated with toxicity. We investigated the feasibility of two intermediate dose-dense FEC regimens. Patients were randomised to six cycles of FEC 75 or FEC 90 , with all three drugs given on day 1 of each 14-day cycle. Patients also received pegfilgrastim 6 mg as a single subcutaneous injection on day 2 of each cycle. The primary efficacy endpoint was the proportion of subjects receiving ≥85% relative dose intensity and was achieved by 96% and 88% of patients in the FEC 75 and FEC 90 arms, respectively. Of 147 FEC 75 infusions, 4.1% were delayed, while 9.8% of 143 FEC 90 infusions were delayed. The most common reasons for delay were adverse events and personal/logistical reasons. One dose reduction occurred during the study (FEC 90 ), related to diarrhoea. Grade 3–4 haematological toxicities were reported in two patients in the FEC 90 arm. There were no incidences of febrile neutropenia during the study. The most common adverse events were increases in liver enzymes and gastrointestinal events; no event resulted in discontinuation. Only one patient (FEC 90 ) experienced serious adverse events (vomiting and throat oedema). In conclusion, dose-dense FEC 75 and FEC 90 are feasible with pegfilgrastim support. These regimens are associated with a very low risk of Grade 3–4 toxicity.
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.